HP
SNDX icon

Harbourvest Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

Harbourvest Partners’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-28,498
Closed -$545K – 75
2021
Q3 		$545K Buy
+28,498
New +$475K 0.05% 44

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Harbourvest Partners's SNDX Position: Q4 2021 in Review

Harbourvest Partners sold out of Syndax Pharmaceuticals (SNDX) in Q4 2021, closing a stake of 28,498 shares — an estimated $545K sold.

Harbourvest Partners first reported a position in SNDX in Q3 2021 and held it in 1 quarter. The position peaked at $545K in Q3 2021. 132 funds tracked by Wall St. Rank hold SNDX as of Q4 2021.

  • Harbourvest Partners reported no remaining Syndax Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Harbourvest Partners sold 28,498 Syndax Pharmaceuticals shares in Q4 2021, an estimated $545K.
  • Harbourvest Partners first reported a position in Syndax Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Harbourvest Partners's Syndax Pharmaceuticals position peaked at $545K in Q3 2021.
  • 132 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2021.

Based on Harbourvest Partners's 13F filing for Q4 2021, filed 14 Feb 2022.